It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
originally posted by: marg6043
a reply to: IAMTAT
I was thinking the same thing, but remember this will go on the democrat states, most Republican states will no care and will not go on lockdown for a virus that is only within certain communities.
This one the elderly in the nation will be laughing their butt offs.
originally posted by: ColdWisdom
Question:
Does anyone on this board actually know anyone personally that has been infected with monkeypox? Like has anyone here directly observed someone with the pox in their immediate circle?
Is it dangerously naive of me to assume that it is all propaganda until it’s right before my eyes?
:
a report from the U.S. Department of Homeland Security's (DHS) Science and Technology Directorate.
The report describes monkeypox as "very stable" in the environment and says it can live "for days to weeks in water, soil, and on refrigerated food." It adds that the virus can live for months to years inside of scabs.
The report does not say how long the virus can survive on surfaces, but the CDC said investigators found the live virus 15 days after a patient's home was left unoccupied, according to one study.
The CDC also said poxviruses like monkeypox can survive in linens, clothing and surfaces particularly well in dark, cool, dry environments. Porous materials like bedding and clothing may harbor live viruses for longer than nonporous materials like plastic, glass, or metal, the CDC said.
originally posted by: DBCowboy
[snip]
BE SAFE!
JYNNEOS
JYNNEOS contains a live Vaccinia virus that does not replicate efficiently in human cells.
It is administered as two (0.5 mL) subcutaneous (under the skin) injections 28 days apart.
The immune response takes 14 days after the second dose for maximal development.
JYNNEOS is licensed by the FDA for use in the prevention of smallpox or monkeypox in people ages 18 years and older. Use in younger populations currently requires requesting and obtaining a single patient emergency use authorization from FDA for each person under 18 years. CDC is developing an Expanded Access Investigational New Drug (IND) protocol to allow broader use of JYNNEOS in the pediatric population.
The effectiveness of JYNNEOS against monkeypox is supported by clinical studies demonstrating a comparable immune response to ACAM2000 and animal studies.
There are no data yet on the effectiveness of JYNNEOS for PEP, PEP++, or PrEP from the current outbreak. Although this is also true for ACAM2000, there is evidence that the precursor for ACAM2000 was effective in eradicating smallpox. Public health officials have concern about the lack of real-world effectiveness data for JYNNEOS, especially because a second dose of JYNNEOS was required in a clinical study to reach the same maximal antibody response seen with ACAM2000 at the 4-week timepoint, and a correlate of protection has not been defined (i.e., it is not known what level of antibodies is needed to prevent Monkeypox virus infection).
Adverse reactions after JYNNEOS include injection site reactions such as pain, swelling, and redness. Fatigue, headache, and muscle pain were the most common systemic reactions observed after JYNNEOS in a clinical trial.
JYNNEOS is safe to administer to people with HIV and eczema or other exfoliative skin conditions.
While there are no data in people who are pregnant or breastfeeding, animal data do not show evidence of reproductive harm; pregnancy and breastfeeding are not contraindications to receiving JYNNEOS.
Please see the JYNNEOS Special Considerations section for guidance on contraindications and precautions and additional clinical considerations for use of JYNNEOS.
ACAM2000
ACAM2000 contains a live Vaccinia virus that is replication competent.
It is administered as one percutaneous dose via multiple puncture technique with a bifurcated needle.
The immune response takes 4 weeks for maximal development.
Following a successful inoculation, a lesion (known as a “take”) will develop at the site of the vaccination; the lesion may take up to 6 weeks or more to heal.
ACAM2000 is licensed by the FDA for use against smallpox; it is allowed for use against monkeypox under an Expanded Access IND (EA-IND) protocol, which requires informed consent along with completing additional forms.
The effectiveness of ACAM2000 is supported by human clinical trials and animal studies.
There are no data yet on the effectiveness of ACAM2000 for PEP, PEP++, or PrEP from the current monkeypox outbreak.
Adverse reactions after ACAM2000 include injection site pain, swelling, and redness; fever; rash; lymph node swelling; and complications from inadvertent inoculation.
ACAM2000 may cause myocarditis and pericarditis. In clinical trials about 1 in every 175 people who got the vaccine for the first time had myocarditis and/or pericarditis within 3 weeks after vaccination.
People with severe allergy to any component of the vaccine should not receive it.
In addition, people with severely weakened immune systems should not receive this vaccine.
ACAM2000 should not be given to infants less than 12 months of age or to people with the following conditions:
Congenital or acquired immune deficiency disorders, including those taking immunosuppressive medications and people living with HIV (regardless of immune status)
Eczema or other exfoliative skin conditions, and people with a history of eczema or other exfoliative skin conditions
Pregnancy
Cardiac disease
Eye disease treated with topical steroids
Moderna may use its mRNA tech for a monkeypox vaccineAmid growing concerns over the potential threat of monkeypox, executives from Moderna said Wednesday they have initiated a research program to consider whether the company could create a monkeypox vaccine with mRNA technology.
originally posted by: Irishhaf
6600 cases and they declare an emergency... LOL, 20k cases of swine flu reported in people each year in the US and they dont care.
This clown show gets worse by the day.